Nothing said here yet.
to join the conversation.
| SCHMITT DANIEL MPresident, CEO and Director | Buy | 140,844 | $50.0K | Wed, Oct 28 |
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib will be assessed in combination with dinutuximab beta plus…
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a…
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic…
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapiesCHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the…
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in elraglusib arm compared to 4% in control…
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 /Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective…
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS inhibitionPreclinical combination results expected in…
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact,…
CHICAGO and FORT WORTH, Texas, Feb.
Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers…